Extendicare Inc.
TSX:EXE.TO · Toronto Stock Exchange
+$0.86 today
Vol 4.59M · Avg 0.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
25.9%
avg 41.3%
ROIC
13.6%
avg 7.8%
ROA
9.1%
avg 6.7%
Analysis
ROE is currently the strongest return metric at 25.9% versus its period average of 41.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael R. Guerriere | Chief Executive Officer, President & Director | $1.60M | — | 61 | — | — |
David E. Bacon | Executive Vice President & Chief Financial Officer | $861,487.00 | — | — | — | — |
John Toffoletto | Senior Vice President, Chief Legal Officer & Corporate Secretary | $800,235.00 | — | — | — | — |
Steve Paraskevopoulos | Senior Vice President of ParaMed & Chief Technology Officer | $695,428.00 | — | — | — | — |
Matthew Morgan | Chief Medical Officer | $574,703.00 | — | — | — | — |
Katie LeMoyne | Senior Vice President & Chief Human Resources Officer | $520,059.00 | — | — | — | — |
Jillian E. Fountain | Vice President of Investor Relations | $291,522.00 | — | — | — | — |
Kathryn Bradley | Senior Vice President of Corporate Development | — | — | — | — | — |
Joe Belinsky | Vice President of Information Technology & Chief Information Officer | — | — | — | — | — |
Mark Trenholm | Senior Vice President of Finance | — | — | — | — | — |
Danielle Labossiere Parr | Vice President of Public Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +52.5% | -2.4% (13yr)3 analysts |
| Revenue | N/A | N/A | -22.6% | +8.0% (13yr)2 analysts |
| Net Income | N/A | N/A | +54.7% | -3.1% (13yr)2 analysts |
| EBIT | N/A | N/A | -7.7% | +3.7% (13yr)2 analysts |
Analysis
Recent growth has been strongest in Net Income at +54.7% over three years. Forward estimates point to Revenue at +8.0% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Trulieve Cannabis Corp.
TRUL.CN
$2.74B
Sienna Senior Living Inc.
TSX:SIA.TO
$2.15B
dentalcorp Holdings Ltd.
DNTL.TO
$2.10B
Cronos Group Inc.
TSX:CRON.TO
$1.40B
WELL Health Technologies Corp.
TSX:WELL.TO
$1.13B
Tilray Brands, Inc.
TSX:TLRY.TO
$785.80M
Medical Facilities Corporation
TSX:DR.TO
$313.45M
CareRx Corporation
TSX:CRRX.TO
$201.13M
Nova Leap Health Corp.
NLH.V
$31.43M
Premier Health of America Inc.
PHA.V
$555,142.00
Who manages EXE.TO?
Extendicare Inc. (EXE.TO) lists 11 active executives. The top listed executive is Kathryn Bradley, Senior Vice President of Corporate Development.
Explore More
Continue the stock analysis
Jump to another research area for this company.